TRT and Prostate Health: Separating Facts from Myths

Written by Adam Maggio | Medically reviewed by Dr. Mitchell Ross, MD, ABAARM

This article clarifies common myths about TRT and prostate health, highlighting current evidence that TRT does not increase prostate cancer risk and can be safely managed under medical supervision. Consult your doctor for personalized advice.

# TRT and Prostate Health: Separating Facts from Myths

Testosterone Replacement Therapy (TRT) has become an increasingly popular treatment for men experiencing symptoms of low testosterone, such as fatigue, decreased libido, and loss of muscle mass. However, concerns surrounding TRT’s impact on prostate health persist, often fueled by myths and misconceptions. This article aims to provide an evidence-based overview of TRT and prostate health, debunk common myths, and offer practical insights for those considering TRT.

---

Understanding Testosterone and the Prostate

What is Testosterone Replacement Therapy?

Testosterone Replacement Therapy involves medically supervised administration of testosterone to restore serum testosterone levels to a normal range in men diagnosed with hypogonadism (low testosterone). TRT can improve quality of life, mood, muscle mass, bone density, and sexual function.

The Prostate and Its Functions

The prostate is a small gland located below the bladder in men, responsible for producing seminal fluid. Prostate health concerns primarily include benign prostatic hyperplasia (BPH), prostatitis (inflammation), and prostate cancer. Since testosterone influences prostate tissue growth and function, it’s natural to question how TRT impacts prostate health.

---

Common Myths vs. Evidence-Based Facts

Myth 1: TRT Causes Prostate Cancer

Fact: The link between testosterone and prostate cancer is more nuanced than widely believed. Early studies suggested high testosterone might fuel prostate cancer growth, leading to caution in TRT use. However, recent large-scale reviews and clinical trials indicate no clear evidence that TRT increases the risk of developing prostate cancer.

  • A 2016 systematic review published in European Urology found no increase in prostate cancer incidence in men undergoing TRT compared to controls.
  • The “saturation model” hypothesis suggests prostate tissue growth responds to testosterone only up to a certain point, beyond which additional testosterone has minimal effect.

    • Myth 2: TRT Exacerbates Benign Prostatic Hyperplasia (BPH)

    Fact: BPH is common with aging and involves prostate enlargement causing urinary symptoms. Research shows that TRT does not significantly worsen BPH symptoms or prostate volume when testosterone levels are restored to physiological norms.

  • A 2019 meta-analysis in The Aging Male concluded that TRT did not increase prostate size or worsen lower urinary tract symptoms (LUTS).
  • Some studies even report symptom improvement due to better muscle strength and pelvic floor function.

    • Myth 3: Men with a History of Prostate Cancer Should Avoid TRT

    Fact: While TRT is traditionally contraindicated in men with active prostate cancer, emerging evidence suggests that carefully monitored TRT may be safe in select men with treated and stable prostate cancer. This is a complex medical decision requiring specialist input.

    ---

    TRT and Prostate Health: What Does the Science Say?

    Monitoring Prostate Health During TRT

    Regardless of myths, monitoring prostate health is essential during TRT. Standard protocols include:

  • Baseline Screening: Digital rectal exam (DRE), prostate-specific antigen (PSA) blood test, and assessment of urinary symptoms.
  • Regular Follow-Up: PSA and DRE every 3–6 months during the first year, then annually if stable.
  • Symptom Tracking: Monitoring for new or worsening urinary symptoms.

    • Evidence on TRT Impact on PSA Levels

    Testosterone can cause a slight increase in PSA levels, but this does not necessarily indicate prostate cancer. Typically, PSA rises modestly after initiating TRT and stabilizes thereafter.

  • A 2017 study in The Journal of Urology showed that PSA increases with TRT are usually within normal limits.
  • Sudden or significant PSA rises warrant further investigation.

    • ---

    Practical Protocol Information

    TRT Administration Forms

  • Injectable Testosterone (e.g., Testosterone Cypionate or Enanthate): Common dosing ranges between 50–100 mg weekly or 100–200 mg every two weeks.
  • Testosterone Gels: Usually applied daily, doses vary from 25–100 mg per day.
  • Testosterone Pellets: Implanted subcutaneously every 3–6 months.

    • Example Protocol (Informational Only)

    | Form | Typical Dose | Frequency |

    |----------------------|-------------------------------------|--------------------|

    | Testosterone Cypionate| 50–100 mg | Weekly |

    | Testosterone Gel | 25–50 mg | Daily |

    > Disclaimer: This dosing information is for educational purposes only and not medical advice